RGEN Quote, Financials, Valuation and Earnings

Enovis Corp. has a net margin of 7.9% compared to Repligen Corp.'s net margin of -104%. Repligen Corp.'s return on equity of 0.09% beat Enovis Corp.'s return on equity of -52.07%.

Repligen Corp. has a consensus price target of $189.22, signalling upside risk potential of 13.74%. On the other hand Enovis Corp. has an analysts' consensus of $47.00 which suggests that it could grow by 78.64%. Given that Enovis Corp. has higher upside potential than Repligen Corp., analysts believe Enovis Corp. is more attractive than Repligen Corp..

Repligen Corp. has a beta of 1.110, which suggesting that the stock is 11.028% more volatile than S&P 500. In comparison Enovis Corp. has a beta of 1.284, suggesting its more volatile than the S&P 500 by 28.371%.

Repligen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enovis Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen Corp. pays -- of its earnings as a dividend. Enovis Corp. pays out -- of its earnings as a dividend.

Repligen Corp. quarterly revenues are $188.8M, which are smaller than Enovis Corp. quarterly revenues of $548.9M. Repligen Corp.'s net income of $14.9M is higher than Enovis Corp.'s net income of -$570.9M. Notably, Repligen Corp.'s price-to-earnings ratio is 6,448.06x while Enovis Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen Corp. is 13.26x versus 0.67x for Enovis Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical, Inc. has a net margin of 7.9% compared to Repligen Corp.'s net margin of 15.47%. Repligen Corp.'s return on equity of 0.09% beat Globus Medical, Inc.'s return on equity of 10.08%.

Repligen Corp. has a consensus price target of $189.22, signalling upside risk potential of 13.74%. On the other hand Globus Medical, Inc. has an analysts' consensus of $98.73 which suggests that it could grow by 11.22%. Given that Repligen Corp. has higher upside potential than Globus Medical, Inc., analysts believe Repligen Corp. is more attractive than Globus Medical, Inc..

Repligen Corp. has a beta of 1.110, which suggesting that the stock is 11.028% more volatile than S&P 500. In comparison Globus Medical, Inc. has a beta of 1.070, suggesting its more volatile than the S&P 500 by 7.046%.

Repligen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen Corp. pays -- of its earnings as a dividend. Globus Medical, Inc. pays out -- of its earnings as a dividend.

Repligen Corp. quarterly revenues are $188.8M, which are smaller than Globus Medical, Inc. quarterly revenues of $769M. Repligen Corp.'s net income of $14.9M is lower than Globus Medical, Inc.'s net income of $119M. Notably, Repligen Corp.'s price-to-earnings ratio is 6,448.06x while Globus Medical, Inc.'s PE ratio is 28.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen Corp. is 13.26x versus 4.42x for Globus Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Teleflex, Inc. has a net margin of 7.9% compared to Repligen Corp.'s net margin of -44.78%. Repligen Corp.'s return on equity of 0.09% beat Teleflex, Inc.'s return on equity of -7.84%.

Repligen Corp. has a consensus price target of $189.22, signalling upside risk potential of 13.74%. On the other hand Teleflex, Inc. has an analysts' consensus of $132.00 which suggests that it could grow by 7.94%. Given that Repligen Corp. has higher upside potential than Teleflex, Inc., analysts believe Repligen Corp. is more attractive than Teleflex, Inc..

Repligen Corp. has a beta of 1.110, which suggesting that the stock is 11.028% more volatile than S&P 500. In comparison Teleflex, Inc. has a beta of 0.954, suggesting its less volatile than the S&P 500 by 4.59%.

Repligen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Teleflex, Inc. offers a yield of 1.11% to investors and pays a quarterly dividend of $0.34 per share. Repligen Corp. pays -- of its earnings as a dividend. Teleflex, Inc. pays out 91.92% of its earnings as a dividend. Teleflex, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Repligen Corp. quarterly revenues are $188.8M, which are smaller than Teleflex, Inc. quarterly revenues of $913M. Repligen Corp.'s net income of $14.9M is higher than Teleflex, Inc.'s net income of -$408.9M. Notably, Repligen Corp.'s price-to-earnings ratio is 6,448.06x while Teleflex, Inc.'s PE ratio is 25.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen Corp. is 13.26x versus 1.73x for Teleflex, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of 7.9% compared to Repligen Corp.'s net margin of 3.93%. Repligen Corp.'s return on equity of 0.09% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Repligen Corp. has a consensus price target of $189.22, signalling upside risk potential of 13.74%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 92.31%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Repligen Corp., analysts believe Xtant Medical Holdings, Inc. is more attractive than Repligen Corp..

Repligen Corp. has a beta of 1.110, which suggesting that the stock is 11.028% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Repligen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen Corp. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Repligen Corp. quarterly revenues are $188.8M, which are larger than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Repligen Corp.'s net income of $14.9M is higher than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Repligen Corp.'s price-to-earnings ratio is 6,448.06x while Xtant Medical Holdings, Inc.'s PE ratio is 76.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen Corp. is 13.26x versus 0.85x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.